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Systematic review of the global epidemiology, 
clinical and laboratory profile of enteric fever
Background Children suffer the highest burden of enteric fever 
among populations in South Asian countries. The clinical features are 
non–specific, vary in populations, and are often difficult to distin-
guish clinically from other febrile illnesses, leading to delayed or in-
appropriate diagnosis and treatment. We undertook a systematic re-
view to assess the clinical profile and laboratory features of enteric 
fever across age groups, economic regions, level of care and antibi-
otic susceptibility patterns.
Methods We searched PubMed (January 1964–December 2013) for 
studies describing clinical features in defined cohorts of patients over 
varying time periods. Studies with all culture–confirmed cases or 
those with at least 50% culture–confirmed cases were included. 242 
reports were screened out of 4398 relevant articles and 180 reports 
were included for final review.
Results 96% of studies were from an urban location, 96% were hos-
pital–based studies, with 41% of studies were from South Asia. Com-
mon clinical features in hospitalized children include high–grade fe-
ver, coated tongue, anaemia, nausea/vomiting, diarrhea, constipation, 
hepatomegaly, splenomegaly neutrophilia, abdominal distension and 
GI bleeding. In adults’ nausea/vomiting, thrombocytopenia and GI 
perforation predominate. The case–fatality rate in children under 5 
years is higher than school aged children and adolescents, and is high-
est in Sub Saharan Africa and North Africa/Middle East regions. 
Multi–drug resistant enteric fever has higher rates of complications 
than drug sensitive enteric fever, but case fatality rates were compa-
rable in both.
Conclusions Our findings indicate variability in disease presentation 
in adults compared to children, in different regions and in resistant 
vs sensitive cases. Majority of studies are from hospitalized cases, and 
are not disaggregated by age. Despite higher complications in MDR 
enteric fever, case fatality rate is comparable to sensitive cases, with 
an overall hospital based CFR of 2%, which is similar to recent glob-
al estimates. This review underscores the importance of further epi-
demiological studies in community settings among children and 
adults, and the need for further preventable measures to curtail the 
burden of disease.
Electronic supplementary material:  
The online version of this article contains supplementary material.
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verity of illness, higher rates of complications and higher 
case fatality rates [6,14,17,20,21].
Although enteric fever is essentially a paediatric disease in 
South Asia, there is dearth of retrospective and prospective 
studies done in children with culture proven enteric fever 
in the global literature [22]. Furthermore, most studies on 
enteric fever represent hospitalized subjects and the differ-
ences in the clinical features and severity of the disease may 
also differ substantially from those not requiring hospital-
ization. Hospitalization rates of up to 2–40% among cul-
ture–confirmed ambulatory enteric cases were found in five 
different study sites in Asia [23], but data from those not 
hospitalized could represent a different disease severity and 
pattern. Differences in health seeking behavior of hospital-
ized vs community based subjects as well as differences in 
access may also limit generalization of available literature 
on clinical patterns of enteric fever [6].
In addition, reports suggest a considerable influence of age; 
with some studies documenting increased morbidity and 
mortality in younger children [19,20,23-25] while others 
[26,27] report comparatively better outcomes in this age 
group. Reports also suggest differences in presentation and 
outcomes between children and adults [19,20,28].Data 
from individual studies suggest a difference in clinical spec-
trum of disease amongst geographical locations in high–in-
come and low and middle–income countries. In a report 
from an Ethiopian children's hospital (1984–1995), intes-
tinal perforation occurred in 27 patients (25%) out of 
which 10 (37%) died [29]. During a similar time (1982–
1995) in Taiwan, only 2/71 cases of intestinal perforation 
were reported in children [30].Prevalence of co–morbidi-
ties such as HIV, differences in antimicrobial resistance pat-
terns, over–the–counter antibiotic availability, substandard 
antibiotic preparations, lack of pipe–borne portable water 
supply, health system functionality and health seeking be-
haviors all weigh in to the differences seen in disease spec-
trum, complications and mortality across regions.
No comprehensive systematic review exists describing the 
differences in clinical features of enteric fever and the fre-
quency of its complications by various age groups. Further, 
the differences in clinical presentation by economic and 
geographical regions and by drug resistance patterns have 
not been systematically investigated.
This systematic review assesses the clinical profile of en-
teric fever across different regions and age groups (chil-
dren vs adults). We also compare the epidemiology of en-
teric in hospitalized and community settings and in 
children infected with multi–drug resistant vs sensitive 
strains of S. typhi. Finally we describe the relationship be-
tween multidrug resistance patterns and case–fatality 
rates over time.
Enteric fever, representing a systemic infection caused by 
Salmonella enteric serovar Typhi (S. typhi) and Salmonella 
enterica serovar Paratyphi (S. paratyphi), is a common cause 
of morbidity in the developing world, particularly in South 
and South–East Asia [1,2]. It is estimated that over 22 mil-
lion cases and more than 200 000 deaths of typhoid fever 
occurred in the year 2000, with the majority of disease bur-
den being borne by children and adolescents in South and 
South–East Asia [1]. Highest incidence has been docu-
mented in impoverished, overcrowded areas with poor ac-
cess to sanitation such as the urban slum areas of North 
Jakarta (Indonesia), Kolkata (India) and Karachi (Pakistan) 
with annual incidence rates of blood culture–confirmed 
enteric fever ranging from 180–494/100 000 among 5–15 
year-olds and 140–573/100 000 among those 2–4 years old 
[3]. However, it is recognized that the assessment of disease 
burden from Africa remains uncertain, with recent reports 
suggesting that it may be an increasingly recognized but 
underreported problem, requiring further prevalence stud-
ies [4-6]. Prevalences ranging from 0% to 4.23% have been 
reported from Kenya, Africa, in a recent review [7].
Despite the high burden of disease, challenges in the diag-
nosis and management of enteric remain. Clinical diagno-
sis of enteric fever is nonspecific and mimics other febrile 
illnesses like malaria and dengue fever and influenza [5,6]. 
This is particularly true for children who can present with 
atypical signs and complications such as neurological dys-
function, nephropathy and cardiac abnormalities [4,8,9] 
and thus lead the clinician away from a diagnosis of enter-
ic fever. Attempts have been made to develop and validate 
clinical algorithms [10,11], without becoming mainstream 
for usage in diagnosis. The lack of availability of the blood 
cultures, in many small hospitals and community settings 
in endemic populations is an additional limitation, as is the 
low yield of the test due to prior antibiotic treatment or 
sampling issues in young children [12,13]. These factors 
can contribute to delayed diagnosis and/or inappropriate 
treatment [12,14].
The emergence of drug resistance and changing patterns of 
both multi–drug (MDR)(resistant to all three traditional 
first–line agents: chloramphenicol; ampicillin; and co–tri-
moxazole) and fluoroquinolone resistant S. typhi and S. 
paratyphi [12,15] has been associated with reported chang-
es in the severity and clinical profile of enteric fever [6,16-
19].Nearly 60% of typhoid fever isolates tested in Kolkata 
and Karachi and 44% of those in Hue, Vietnam were resis-
tant to nalidixic acid; making these cases less responsive to 
commonly used second line agents such as ciprofloxacin 
and other fluoroquinolones [3,14]. This has not only nar-
rowed the therapeutic options in high disease burden 
countries but has also lead to increased treatment costs, se-
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METHODS
We searched PubMed for studies limited to Humans (1964 
onwards; last searched December 2013), and English lan-
guage using MeSH and text words as shown in Figure 1. 
We conducted additional parallel searches for the follow-
ing to ensure comprehensive identification of all relevant 
reports: a) non–English language studies (title/abstracts 
screen); b) clinical trials; c) relevant articles were manually 
retrieved from reference lists and other pertinent studies, 
known to the authors and not already retrieved from 
PubMed were included (“author’s collection”).
All studies indicating documentation of clinical features, 
based on title and/or abstract, were retrieved in full–text 
where available (Figure 1). Regional break–up of countries 
was taken from the World Bank list of Economies (updated 
April 2012) [31].
Inclusion criteria
We included studies which reported clinical features from 
diagnosed cases of enteric fever. Diagnosis was based on 
either a positive culture (blood, bone marrow, other sterile 
site–stool, urine) or a positive serological diagnostic test 
(Widal test/Typhi Dot test), as long as the diagnosis was 
confirmed by culture tests in at least 50% of these cases. 
Outcome data in children (age as author defined, or 0–15 
years) or adults (age as author defined, or 12 years and 
above) was included if given in disaggregated form. We in-
cluded clinical trials, vaccine trials, diagnostic studies, only 
where any clinical features were described provided they 
met the pre–defined criteria (Box 1).
Exclusion criteria
We excluded case reports (as indexed, or those with a sam-
ple size ≤5), studies reporting mixed age groups (ie, 2 to 
55 years) where disaggregation on age was not stated, with 
some or all cases diagnosed only on clinical suspicion and 
reports of selective patient groups (eg, all complicated, or 
all HIV cases, or all cases presenting with diarrhea). Stud-
ies using only a clinical diagnosis or serological diagnostic 
tests only (Widal test/Typhi Dot test), without culture con-
firmation were excluded. For studies reporting data for S. 
Figure 1. Search methodology. 
*Mixed ages, no clinical features or 
excluded complicated cases on 
enrollment. †“Others” (1024) 
includes: Studies on Typhoid 
carriers (44) Non-typhoid (mostly 
Rickettsia)/diarrheal diseases/other 
Salmonella (561) General public 
health/sanitation (58) Not relevant/
other laboratory-based/miscella-
neous (112) Reviews, letters, 
editorials (249). ‡“Others” (n = 20) 
includes: Non-typhoid(mostly 
Rickettsia)/diarrheal diseases/other 
Salmonella (n = 1), General public 
health/sanitation (n = 1), Not 
relevant/other laboratory-based/
miscellaneous (n = 14), Reviews, 
letters, editorials (n = 5).
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typhi and S. paratyphi separately, only data for S. typhi were 
extracted; however if studies did not present data separate-
ly, data was included as both S. typhi and S. paratyphi.
In addition to baseline characteristics, geographical loca-
tion, resistance and clinical features, data were also extract-
ed separately where available for different age groups and 
for multi–drug resistance and sensitive isolates. Clinical 
features were used as author defined or as a given set of 
definitions if otherwise undefined (Chart 1 in Online Sup-
plementary Documentation). For each clinical feature, we 
extracted the number of patients with the event and the 
number of patients assessed for the feature. Similar features 
were grouped together (such as “encephalopathy” and 
“lethargy” grouped under “altered mental status”); the larg-
est uncombined numerator was used when several similar 
features were reported in a study.
Statistical methods
Data was double entered into Microsoft Access 2007 and 
tabulated using Microsoft Excel 2007 (Microsoft Corp., 
Redmond, WA, USA) spreadsheets. Frequency tables of 
clinical features were calculated also using Microsoft Excel. 
Further analysis was done using χ2–testing for different ages 
(0–5 years vs 5–10 years; children 0–5 years and 5–10 
years vs adults), for economical/geographical regions (Af-
rica vs South Asia); for hospital vs community settings and 
for MDR strains vs sensitive strains). The level of signifi-
cance was set at <0.05and odds ratio (OR) are reported for 
likelihood of clinical feature between different categories. 
All analysis was done using OpenEpi [32].
RESULT
Included studies
242 reports were screened out of a total of 4398 articles 
retrieved with the search strategy (Stage 1). All studies with 
culture (blood, bone marrow, other sterile site stool, urine) 
confirmed enteric fever were included, as well as serologi-
cally confirmed enteric fever if percentage of culture con-
firmed cases was more than 50% (Stage 2). Disaggregated 
age data from these studies, if available, were also extracted 
assuming a similar proportion of culture–confirmed cases 
in each age group. Categorization of excluded studies is 
shown in Figure 1.
A total of 180 reports were included for final review. Fig-
ure 2 summarizes the characteristics of included studies 
(153 primary references and 27 references with overlap-
ping data): 82 studies were on children, 63 on adults and 
8 studies provided disaggregated data for adults and chil-
dren (2 reports from overlapping or potentially overlapping 
data). Urban, hospital–based, inpatient retrospective stud-
ies were predominant. Data for resistance and relapse were 
Box 1. Pre-set inclusion criteria
  1.  Studies must have clearly documented data on at least one 
clinical feature (other than drug resistance or mortality)
  2.  Studies were included from 1964 onwards as well as ar-
ticles not indexed in PubMed before that at the time of 
searching
  3.  Number of cases reported on in each study had to be more 
than 5 (n ≥5)
  4.  Studies with cases of only S. typhi were included, unless 
data was given for both S. typhi and S. paratyphi in an ag-
gregated form which could not be separated
  5.  Studies must include enteric fever of all severity (eg: ex-
cluded if only uncomplicated cases were included)
  6.  Studies must have at least 50% or more culture positivity 
(blood, bone marrow, urine or stool) along with serologi-
cally positive cases (not included if only diagnosed on 
clinical basis)
  7.  Cases must be in distinct age groups–children or adults
  8.  Studies must not be from a certain population subset (eg, 
all HIV positive, all intestinal perforations)
  9.  Studies that were not in English must have adequate, ex-
tractable information in the abstract
10.  Studies published from the same hospital/region and dur-
ing the same time period were considered as duplicate/
overlapping data and counted once using the largest re-
ported denominator
Figure 2. Breakdown of 
included studies.  
8 studies with disaggre-
gated data for Adults and 
Children are counted 
only once in Child 
category, 27 studies had 
overlapping/duplicate 
data (Total 180). MD 
– multidrug resistance; 
FQ – fluoroquinolones.
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uncommonly presented. Studies with only S.typhi were 
72%, while 28% had representation of both S. typhi and S. 
paratyphi which could not be separated out. Figure 3 
shows the geographical representation of countries with 
included studies with the relative contribution of data from 
different regions. India far outranked other countries, with 
46 studies in total (41% of included studies).
Epidemiology of enteric fever in children vs 
adults
Studies in adults and those with data from children in dis-
aggregated age groups were tabulated, from all available 
settings (Table 1 and Table S1 in Online Supplementary 
Document). Fever was universal (97%–100%) and a coat-
ed tongue was consistently noted in all children's age 
groups (71%–85% range). Signs and symptoms such as 
anaemia (71%), leukocytosis (47%), hepatitis (36%) and 
hepatomegaly (50%) were more common among pre–
school children (under 5 years) than in other age groups, 
while headache and abdominal pain/tenderness was re-
ported to be less common in this age group (14% and 20% 
respectively). Altered mental status (30%), signs of URTI 
(22%), leucopenia (57%), abdominal pain/tenderness 
(70%) were common in school–aged children. Headache 
(75%), abdominal distension (66%), cough (60%) and 
pneumonia (19%) were more common in older children 
aged 10–17 years. In contrast, more adults presented with 
nausea/vomiting (49%), splenomegaly (39%), GI perfora-
tion (5%), and thrombocytopenia (52%). Relative brady-
cardia, chills/rigors and dehydration were also frequently 
reported. Toxicity throughout the ages was found to be 
26–38%. GI perforation was more common as age in-
creased. Children were infected with MDR strains in 22–
25% cases, as compared to more than half of enteric cases 
in adults which were MDR. Relapse was similar in all ages, 
but pre–schoolchildren had the highest fatality rates (6%), 
compared to all other age groups.
In comparing children 0–5 years with children aged 5–10 
years, different features were found to be more likely to oc-
cur (Table S2 in Online Supplementary Document), and 
after pooling data for children under 10 years compared to 
adults (author defined ages or aged 12 and above), the fea-
tures more likely to occur in children are shown in and 
Table S3 in Online Supplementary Document.
Regional spectrum of enteric fever in 
children
Data was provided from above referenced studies on chil-
dren as well as age disaggregated studies–in total 90 stud-
ies (Table 2 and Tables S1 and S2 in Online Supplemen-
tary Document). In almost all regions, 40% of enteric 
cases presented after receiving prior antibiotics. MDR en-
teric fever was highest in the Middle East & North Africa 
from 3 studies, followed by South Asia. Fluoroquinolone 
resistance was reported rarely in almost all regions. The 
most common feature globally was fever. Other common 
features were anaemia (highest in South Asia), hepatomeg-
aly (commonest in East Asia & Pacific), and coated tongue. 
Toxicity and relative bradycardia was seen highest in Sub 
Saharan Africa. Diarrhea was more common than consti-
Figure 3. Map of geographical distribution of included studies.
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pation, except in East Asia/Pacific. Sub Saharan Africa and 
Middle East/North Africa had a higher occurrence of ab-
dominal distension and ileus, as well as GI perforation 
(6%). High income countries reported more weakness/mal-
aise, rose spots and an intermittent pattern of fever. Relapse 
was consistently low: 2–9% and case–fatality rate ranged 
from 1–6%, highest in Sub Saharan Africa and North Af-
rica/Middle East regions.
In comparing Africa (Sub Saharan Africa and Middle East/ 
North Africa) to South Asia, significant findings more like-
ly to occur in children from African countries are present-
ed in Table S6 in Online Supplementary Document.
Hospital vs community–based studies in 
children
Data was derived from 83 prospective or retrospective stud-
ies or treatment trials of hospitalized, predominantly inpa-
tient children from urban areas (Table 3 and Table S7 in 
Online Supplementary Document). Data meeting the pre–
defined criteria was scarce other than from hospital based 
studies, and could be extracted from only 6 studies conduct-
ed in community settings or health centers (outpatient) on 
children. Hospitalized children (Table S8 in Online Supple-
mentary Document) presented most commonly with high–
grade fever (odds ratio (OR) 4.7, 95% confidence interval 
(CI) 3.5–6.4), hepatomegaly (OR 7.1, 95% CI 4.2–12.0), 
nausea/vomiting (OR 2.0, 95% CI 1.6–2.6), abdominal dis-
tension (OR 7.4, 95% CI 2.7–20.0), and coated tongue, 
anaemia and neutrophilia. Diarrhea (OR 5.2, 95% CI 3.8–
7.2) and constipation (OR 4.2, 95% CI 1.9–9.6) were also 
associated more in hospitalized children. Other findings 
more likely to occur in hospitalized children were spleno-
megaly (OR 2.7, 95% CI 1.7–4.0); GI bleeding (OR 9.0, 95% 
CI 1.2–64.4); pre–treatment antibiotics received (OR 2.8, 
95% CI 2.0–4.0) and duration of illness ≤1week (OR 1.8, 
95% CI 1.3–2.4). Rose spots were an uncommon finding 
(5%). In all of the isolates reported in these studies, MDR 
Table 1. Epidemiology of enteric fever by age (references to studies in Online Supplementary Document)
0–5 years (15 studies)* 5–10 years (8 studies)† 10–17 years (5 studies)‡ adults 12 years (73 studies)§
n N % n N % n N % n N %
Signs and symptoms–systemic:
Fever 265 274 97 194 194 100 39 39 100 2287 2337 98
High grade fever 11 77 14 111 292 38
Headache 15 104 14 70 125 56 6 8 75 1149 1830 63
Toxicity 169 492 34 184 586 31 70 268 26 208 543 38
Rash or rose spots 2 12 17 6 93 6 5 84 6 75 982 8
Coated tongue 28 33 85 154 190 81 32 45 71 490 881 56
Respiratory and abdominal:
Cough 58 187 31 78 231 34 32 53 60 595 1459 41
Nausea or vomiting 61 193 32 88 194 45 5 39 13 792 1628 49
Diarrhea 286 665 43 173 752 23 94 276 34 1118 2407 46
Constipation 52 439 12 177 752 24 31 276 11 382 1570 24
Hepatomegaly 261 526 50 276 630 44 93 245 38 555 1903 29
Splenomegaly 165 635 26 228 789 29 71 290 24 883 2278 39
Abdominal pain or tenderness 29 143 20 136 194 70 19 39 49 981 1827 54
Abdominal distention or ileus 24 131 18 90 190 47 35 53 66 139 831 17
Laboratory features:
Anaemia (Hb <12 g/dl) 50 70 71 21 31 68 487 1687 29
Leukopenia (<5 × 103/µL) 17 81 21 71 125 57 800 2248 36
Leukocytosis (>15 × 103/µL) 198 417 47 91 558 16 27 237 11 32 238 13
Complications:
Shock or hypotension 3 63 5 9 97 9 0 36 0 145 1559 9
Altered mental status 27 197 14 86 287 30 4 75 5 972 3339 29
Pneumonia or chest signs 28 194 14 57 318 18 15 81 19 205 1921 11
GI bleeding 8 158 5 11 189 6 6 75 8 177 2557 7
GI perforation 1 127 1 5 194 3 0 31 0 110 2183 5
Outcome:
Relapse 18 399 5 29 614 5 14 273 5 66 1516 4
Death 38 656 6 10 751 1 1 75 1 197 4698 4
n – number with feature, N – number assessed
*Includes studies with data for under 1, under 2, under 3 and under 4 year–olds.
†Includes studies with data for 5 to 12, 5 to 13 and 6 to 12 year–olds.
‡Includes studies with data for 10 to 14, 10 to 15 and 10 to 17 year–olds.
§Includes a large number of adolescents, since author definition of adults was very varied (eg: 12 years and above, 15–59 years).
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was higher in hospitalized children compared to commu-
nity based studies (OR 1.7, 95% CI 1.3–2.1).The most com-
mon complications in hospitalized children was DIC (18%), 
followed by pneumonia, arthritis/arthralgia, altered mental 
status, hepatitis, and meningitis (8–15%).
MDR vs sensitive isolates in children
Thirty six studies provided either disaggregated data for 
MDR and drug sensitive enteric fever or had all sensitive 
or all MDR isolates (Table 4 and Table S9 in Online Sup-
plementary Document). Children infected with MDR iso-
lates (sample size range from 11 to 1647) (Table S10 in 
Online Supplementary Document) presented late (dura-
tion of illness >1week) (OR 2.7, 95% CI 2.1–3.4) with pri-
Table 2. Spectrum of enteric fever by economic and geographical regions (references to studies in Online Supplementary Docu-
ment)
HigH income countries 
(17 studies)
europe & central 
asia (4 studies)
sub–saHaran africa 
(12 studies)
middle east & n. 
africa (3 studies)
soutH asia
(41 studies)
east. asia & p 
acific (11 studies)
N N % n N % n N % n N % N N % n N %
Demographics/history:
Blood/bone marrow isolates 540 710 76 122 131 93 1069 1382 77 250 281 89 5280 5736 92 891 1012 88
Pre–treatment antibiotics 10 13 77 6 80 8 15 35 43 1804 3152 57 255 570 45
Duration of illness ≤1 week 68 161 42 343 574 60 92 150 61 879 2013 44 203 325 62
Multi–drug resistant isolates 10 288 3 0 72 0 0 120 0 60 60 100 1885 4214 45 150 459 33
Fluoroquinolone resistance 0 12 0 0 8 0 25 1169 2 0 326 0
Signs and symptoms–systemic:
Fever 614 639 96 119 123 97 920 1005 92 103 131 79 4490 4800 94 673 688 98
High grade fever 3 13 23 72 72 100 204 438 47 2085 3178 66 68 126 54
Relative bradycardia 77 271 28 2 96 2 285 573 50 12 150 8 21 482 4 40 258 16
Headache 115 481 24 64 123 52 374 909 41 73 131 56 425 3730 11 209 609 34
Toxicity 1 71 1 198 378 52 8 71 11 1072 3486 31 83 231 36
Rash or rose spots 97 523 19 6 104 6 1 792 0 9 221 4 7 960 1 38 542 7
Dehydration 31 111 28 3 24 13 66 278 24 22 71 31 3 50 6 18 167 11
Coated tongue 81 150 54 314 608 52 140 195 72
Respiratory and abdominal:
Cough 122 434 28 23 96 24 146 426 34 149 281 53 530 2823 19 263 786 33
Nausea or vomiting 229 582 39 16 51 31 211 535 39 33 71 46 1634 4556 36 287 684 42
Diarrhea 269 609 44 26 51 51 592 1161 51 43 131 33 1335 4503 30 308 922 33
Constipation 73 383 19 3 24 13 61 324 19 0 0 254 3895 7 240 772 31
Hepatomegaly 145 414 35 79 123 64 103 405 25 62 131 47 2060 4510 46 545 801 68
Splenomegaly 168 512 33 55 123 45 153 555 28 195 281 69 1441 4714 31 239 989 24
Abdominal pain tenderness 215 555 39 20 51 39 420 975 43 77 131 59 978 3782 26 385 786 49
Abdominal distention or ileus 20 206 10 9 51 18 236 809 29 103 221 47 254 4097 6 198 732 27
Laboratory features:
Anaemia (Hb <12 g/dl) 78 209 37 11 25 44 410 936 44 16 62 26 2284 3132 73 191 566 34
Leukopenia (<5 × 103/µL) 84 408 21 16 49 33 89 365 24 12 69 17 204 2069 10 213 653 33
Leukocytosis (>15 × 103/µL) 1 41 2 3 49 6 14 113 12 11 69 16 384 1754 22 12 177 7
Complications:
Shock or hypotension 2 50 4 4 131 3 4 71 6 123 2606 5 10 278 4
Altered mental status 51 417 12 44 123 36 155 1127 14 414 4928 8 191 786 24
Pneumonia or chest signs 19 305 6 1 24 4 267 993 27 66 150 44 227 1966 12 66 785 8
GI bleeding 19 548 3 2 24 8 37 1069 3 1 150 1 82 1385 6 24 616 4
GI perforation 4 449 1 63 996 6 1 150 1 13 943 1 3 274 1
Outcome:
Relapse 34 560 6 4 58 7 34 938 4 18 210 9 194 3614 5 7 326 2
Death 5 567 1 5 131 4 79 1328 6 10 210 5 83 4981 2 7 922 1
n – number with feature, N – number assessed
or antibiotic treatment. Children infected with MDR strains 
were more toxic (OR 2.1, CI 1.6–2.6) and had relatively 
higher frequency of complications and adverse outcomes. 
Complications such as abdominal distention or ileus (OR 
2.6, 95% CI 1.7–4.1), GI bleeding (OR 2.3, 95% CI 1.1–
4.5), shock/hypotension (OR 2.9, 95% CI 1.2–7.3); myo-
carditis (OR 4.2, 95% CI 1.4–12.5) and pneumonia (OR 
2.2, 95% CI 1.3–3.7) were higher in cases of MDR isolates 
compared to pan–sensitive isolates. High grade fever (OR 
0.6, 95% CI 0.5–0.8), relapse (OR 0.3, 95% CI 0.1–0.7); 
leucopenia (OR 0.5, 95% CI 0.3–0.8); thrombocytopenia 
(OR 0.1, 95% CI 0.03–0.4) and arthritis or arthralgia/my-
algia (OR 0.05,95% CI 0.01–0.4) were more frequent in 
children with sensitive isolates (sample size range from 13 
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to 2531). The case fatality was 1.0% vs 1.3% in resistant 
and sensitive enteric respectively.
Other significant features more likely to be seen in MDR 
cases are shown in Table S10 in Online Supplementary 
Document.
DISCUSSION
Despite advances in public health and hygiene that have 
led to a disappearance of enteric fever from much of the 
Table 3. Enteric fever in children in hospital–based vs commu-
nity/health–center (references to studies in Online Supplemen-
tary Document)
Hospital–based (83 
studies)
community–based 
or HealtH center 
(out–patients) (6 
studies)
n N % n N %
Demographics/history:
Blood/bone marrow isolates 7693 8786 88 407 407 100
Pre–treatment antibiotics received 2047 3709 55 43 141 30
Duration of illness ≤1week 1520 3034 50 69 193 36
Multi–drug resistant isolates 2018 4856 42 93 313 30
Fluoroquinolone resistance 11 1433 1 9 44 20
Signs and symptoms–systemic:
Fever 6327 6787 93 394 395 100
High grade fever 2372 3622 65 60 209 29
Bradycardia or relative bradycardia 437 1830 24
Headache 1088 5577 20 169 368 46
Toxicity 1338 4171 32 18 28 64
Rash or rose spots 158 3142 5
Dehydration 143 701 20
Coated tongue 535 953 56
Respiratory and abdominal:
Cough 1153 4588 25 62 190 33
Nausea or vomiting 2300 6038 38 95 407 23
Diarrhea 2512 6886 36 42 423 10
Constipation 625 5209 12 6 193 3
Hepatomegaly 2946 6175 48 16 141 11
Splenomegaly 2193 6937 32 25 169 15
Abdominal pain or tenderness 1901 5873 32 186 369 50
Abdominal distention or ileus 814 5889 14 4 189 2
Laboratory features:
Anaemia (Hb <12 g/dL) 2976 4908 61
Leukopenia (<5 × 103/µL) 602 3442 17 15 137 11
Leukocytosis (>15 × 103/µL) 399 2033 20 17 136 13
Complications:
Shock or hypotension 143 3136 5
Altered mental status 853 7343 12
Pneumonia or chest signs 647 4232 15
GI bleeding 164 3603 5 1 189 1
GI perforation 84 2812 3
Outcome:
Relapse 291 5706 5
Death 181 7909 2 0 209 0
n – number with feature, N – number assessed, Hb – hemoglobin, GI – 
gastrointestinal
Table 4. Demographic and clinical features of enteric fever in 
children with multi–drug resistant vs sensitive strains of S. typhi 
and S. paratyphi (references to studies in Online Supplementa-
ry Document)
multi–drug resistant 
(14 studies)
sensitive (22 
studies)
n N % n N %
Demographics/history:
Multi–drug resistant isolates 1647 1647 100 0 2531 0
Chloramphenicol resistance 125 125 100 9 293 3
Fluoroquinolone resistance 0 183 0 5 55 9
Blood/bone marrow Isolates 1121 1121 100 1600 1616 99
Pre–treatment antibiotics received 10 11 91 71 335 21
Duration of illness ≤1week 151 417 36 627 1034 61
Signs and symptoms–systemic:
Fever 620 653 95 1350 1393 97
High grade fever 441 552 80 945 1090 87
Bradycardia or relative bradycardia 7 62 11 3 218 1
Headache 116 220 53 122 382 32
Toxicity 208 427 49 316 1006 31
Rash or rose spots 3 153 2 11 292 4
Dehydration 6 15 40 11 190 6
Coated tongue 34 77 44 8 13 62
Respiratory and abdominal:
Cough 92 256 36 151 487 31
Nausea or vomiting 140 332 42 128 371 35
Diarrhea 201 638 32 464 1358 34
Constipation 52 487 11 137 1203 11
Hepatomegaly 456 725 63 699 1639 43
Splenomegaly 320 694 46 433 1669 26
Abdominal pain or tenderness 294 600 49 358 1259 28
Abdominal distention or ileus 55 260 21 40 434 9
Laboratory features:
Anaemia (Hb <12 g/dL) 296 442 67 656 1170 56
Leukopenia (<5 × 103/µL) 20 362 6 132 1177 11
Leukocytosis (>15 × 103/µL) 80 300 27 231 914 25
Complications:
Shock or hypotension 20 115 17 7 105 7
Altered mental status 80 586 14 83 638 13
Pneumonia or chest signs 32 219 15 35 484 7
GI bleeding 28 382 7 12 357 3
GI perforation 4 142 3 1 136 1
Outcome:
Relapse 7 329 2 12 151 8
Death 23 1647 1.0 31 2339 1.3
n – number with feature, N – number assessed
developed world, it still remains the commonest bacterae-
mic illness in South Asian countries with children being 
especially susceptible [1,14]. The emergence of multi–drug 
resistance is very concerning due to the limited therapeutic 
options, high financial implications and its continuing bur-
den in impoverished, low–income countries [6,14,21].
Several limitations should be recognized in considering our 
data. Our inclusion of culture proven and serological con-
firmed cases with culture confirmation in at least 50% of 
these cases may not reflect the true clinical features profile 
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of enteric fever. With the high prevalence of prior antibi-
otic treatment, culture proven diagnosis may have been 
falsely low. On the contrary, exclusion of clinically diag-
nosed cases may also have resulted in missing out enteric 
fever with atypical features. An overwhelming majority of 
included studies were from urban areas, with many stud-
ies from rural areas excluded for reasons such as mixed re-
porting of adults and children, or diagnosis solely on clin-
ical features (Box 1). Many community level studies were 
also excluded due to similar reasons. Existing literature 
gives a varying, non–standardized representation of enter-
ic fever since there are differences in definitions such as 
adult/pediatric age group cutoffs, relapse, altered mental 
status and other clinical features. Case series (such as “all 
complicated cases excluded”, or “all with diarrhea”) were 
excluded as well. Paratyphoid fever was not included to be 
reviewed in this systematic review as it has a different clin-
ical spectrum, however in 28% of cases data could not be 
separated from typhoid fever.
Outcomes such as resistance, relapse, and mortality were 
not reported in all studies, leading to an incomplete repre-
sentation. Confounders, such as co–morbidities, resistance, 
socio–economic status, heterogeneous access to health 
could not be adjusted for since individual level data were 
not analyzed. Current trends in resistance especially nali-
dixic acid resistance and emerging fluoroquinolone resis-
tance have not been extensively reported. Most studies 
were from South Asia, especially India and Pakistan. Re-
gions were categorized based on the World Bank list of 
economies, which gives geographic classifications for low–
income and middle–income economies only, while high 
income countries that may reflect any geographical region 
with an improved developmental status. Furthermore, our 
review is not fully representative of non–English language 
speaking regions of the world, although data from trans-
lated abstracts were used where possible.
Notwithstanding the above, our review highlights a num-
ber of key findings of the epidemiological pattern of en-
teric fever in different categories, which will assist the cli-
nician in his diagnosis and help in the fight against enteric 
fever. Most of our data are from urban, hospitalized chil-
dren who were more likely to have the following features: 
high–grade fever, nausea/vomiting, diarrhea, constipation, 
hepatomegaly, splenomegaly, neutrophilia, abdominal dis-
tension and GI bleeding. Young children (under 5 years) 
were more likely to show anaemia, diarrhea, leukocytosis, 
hepatitis and hepatomegaly and had a higher mortality. 
Older children commonly showed an altered mental status, 
signs of URTI leucopenia, and abdominal pain/tenderness. 
Adults were more likely to present with splenomegaly, GI 
perforation, and thrombocytopenia.
In previous literature, the commonest complications are 
reported to be gastrointestinal bleeding, intestinal perfora-
tion, encephalopathy and shock [5,14,33], though our re-
view suggests that DIC, pneumonia, arthritis/arthralgia al-
tered mental status, hepatitis, and meningitis predominate. 
The high frequency of DIC in our review was determined 
from 4 studies with one study forming the majority of the 
data [17]. Of note, the ‘classic’ stepladder temperature pat-
tern [34] was only present in 25% of adult patients. 
Amongst children in the preschool years, a high case–fatal-
ity rate of 6% was found from the included studies, and 
death was 4.5 times more likely to occur compared to 
school–aged children. One included study had a particu-
larly strong association of mortality in younger children 
with anaemia [17]. This high mortality and high incidence 
[25,35] identifies this age group as a high risk group to be 
addressed for vaccinations.
Other related or underlying factors influencing the clinical 
profile and outcomes of enteric fever are varying strain vir-
ulence, inoculum size, delays in or duration of treatment 
received, numerous host factors such as immune response, 
co–existing illnesses or infections, or underlying malnutri-
tion [5,12,36]. These findings must be considered with 
caution, as our review was limited to studies with full re-
porting of clinical features and many studies with only out-
come data were excluded. Others have recently reported 
increased disease severity with emergence of fluoroquino-
lone resistance [37].
There is insufficient and inconsistent reporting of clinical 
features data in MDR isolates, especially in the 1980s when 
the first few outbreaks were reported [5]. This may be due 
to a publication bias, since chloramphenicol resistance data 
was being reported at 10% from that time period [5].The 
complications are higher with multi–drug resistant strains 
and these isolates have been shown to be more virulent 
than sensitive strains [38,39].In this review, the case–fatal-
ity rates from all resistant and all sensitive S. typhi were al-
most the same (1.0% in MDR strains vs 1.3% in sensitive 
strains), reflecting a general decrease in overall mortality in 
treated cases since the advent of antibiotic usage and im-
proved health care, as our review is mostly derived from 
inpatient reports (77% of studies).
The case fatality rate of 2% from 83 studies in hospitalized 
children, is comparable to case–fatality rates reviewed by 
Crump et al. [18] from 10 population–based studies (al-
though in mixed age groups) which showed a range of 
0–1.8%. However, regionally, Sub–Saharan Africa, and 
North Africa and Middle East had the highest case–fatality 
rates (5–6%). The relapse rate was low, ranging from 2–9% 
in all regions, reflecting improved hospital care and initia-
tion of antibiotics, while regional differences in case–fatal-
ity rate ranged from 1–6%, highest in Sub Saharan Africa 
and North Africa/Middle East regions. This may reflect the 
higher rate of complications such as GI perforation, GI 
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bleed and pneumonia in these regions. As this data spans 
studies prior to the onset of improved health care access and 
surgical treatments, as well as after it reflects the overall pic-
ture of mortality enteric fever has posed on each region.
Widespread antibiotic pre–treatment was present in all re-
gions, except Europe and Central Asia, due to prevalence of 
self–medication and poor health–seeking behaviors [40]. 
This has implications for the development of newer diagnos-
tic tests that can replace blood culture, and ideally be more 
rapid, specific and cost-effective as well as sensitive. Rational 
use of antibiotics based on culture sensitivity patterns in dif-
ferent regions in imperative in curtailing the further evolu-
tion of multi–drug resistance which is already rife.
Applicability and implications for research
Although enteric fever is essentially a pediatric disease in 
South Asia, there is a serious dearth of data from children 
in community settings in global literature [3,23,25,41-43]. 
Hospital–based data helps show severity of infection and 
outcomes associated with treatment, but capturing data on 
clinical features from studies based in the community is 
imperative to strengthen our ability to pick and treat en-
teric fever in the most vulnerable and to better understand 
presentation of drug resistance and treatment outcomes of 
mild enteric fever. Treatment requires a low threshold for 
empirical antibiotics but this must be weighed against the 
growing rates of resistance in many regions that make treat-
ment options complex and costly. The solution will have 
to be multi–faceted and include improved sanitation, vac-
cination implementation in high–risk populations in com-
bination with rapid diagnosis, elimination of carriers, and 
rational use of the antibiotic options. Vaccinations as part 
of national immunizations programs (EPI) for those under 
2 years of age in high risk populations will have to be the 
key in restriction of the spread of disease through reducing 
both disease transmission and new carriers, until water and 
sanitation are universally upgraded [33,44,45].
Future studies should be designed keeping these gaps in 
mind and focus on community based enteric cases. De-
scriptions of all clinical features, resistance patterns and 
mortality should be a primary objective of researchers in 
treatment trials, vaccine trials and prospective/retrospective 
studies, preferably in separate cohorts based on age (chil-
dren vs adults), using standardized, clearly defined age cat-
egories. The cut–offs for MIC for fluoroquinolones have 
been recently revised and reports should include referenc-
es of the MIC used by their laboratory. There is a need for 
randomized control trials for appropriate outpatient ther-
apy in the face of rising resistance to commonly used anti-
microbials.
Surveillance networks
There is a need to establish a consortium for reporting of 
enteric fever, especially with regard to AMR (antimicrobial 
resistance) as well as a central repository for genomic stud-
ies, looking at SNP related to enteric severity. The Coalition 
Against Typhoid [46] for example, is a global forum of 
health and immunization experts working to expedite and 
sustain evidence–based decisions at the global, regional 
and national levels regarding the use of enteric vaccination 
to prevent childhood enteric fever. They state the need to 
develop long and short term goals for enteric control, 
which include for the short term high burden and at risk 
populations immunizations, good hygiene practices, and 
for long term improvements in access to safe water and im-
proved sanitation as their goals.
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